Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | NCF1 | P14598 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP7 | P55210 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583086 | 0.78 | MAOA (0.54) | MAOANCF1MAOBKDM4EGPR3 | |
| SCHEMBL28220033 | 0.78 | MAOA (0.54) | MAOANCF1MAOBKDM4EGPR3 | |
| SCHEMBL203711 | 0.78 | LMNA (0.55) | MAOANCF1KDM4EGPR3PI4KA | |
| SCHEMBL29742219 | 0.78 | LMNA (0.55) | MAOANCF1KDM4EGPR3PI4KA | |
| Ammonia Solution, Strong SCHEMBL6035045 | 0.77 | LMNA (0.53) | MAOANCF1KDM4EGPR3PI4KA | |
| SCHEMBL2708504 | 0.76 | NR4A2 (0.59) | NR4A2ALDH1A1CASP1SMN1; SMN2HSD17B10 | |
| SCHEMBL601463 | 0.75 | MAOA (0.50) | MAOANCF1MAOBKDM4EGPR3 | |
| SCHEMBL6822558 | 0.75 | MAOA (0.50) | MAOANCF1MAOBKDM4EGPR3 | |
| SCHEMBL11295043 | 0.75 | ERN1 (0.55) | MAOANCF1MAOBKDM4EGPR3 | |
| SCHEMBL31384389 | 0.75 | MAOA (0.50) | MAOANCF1MAOBKDM4EGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | claimed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | claimed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | claimed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | claimed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | claimed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | claimed |
| EP-0288072-A2 | 3-Amino-4-(ethylthio)-quinoline or its acid addition salts for use as medicament and medicament containing it | EGIS GYOGYSZERGYAR (HU) | 1988-10-26 | — | — | EP | claimed |
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2024187049-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | DUKE UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| EP-4291569-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | Duke University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230090437-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-03-23 | — | — | US | disclosed |
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | AMGEN INC. | 2003-05-22 | — | — | US | disclosed |
| US-6440973-B1 | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC. | 2002-08-27 | — | — | US | disclosed |
| US-6180643-B1 | ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR | AMGEN INC. | 2001-01-30 | — | — | US | disclosed |
| CN-1246856-A | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0948495-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | Amgen Inc., (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998022457-A9 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022457-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090437-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IRF3, IFNG, STING1 | MAOA 3254/4885NCF1 1958/4885MAOB 3173/4885 |
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | TNF, IL1A, IL6 | MAOA 2252/4885NCF1 782/4885MAOB 2957/4885 |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | MAOA 3504/4885NCF1 1358/4885MAOB 4119/4885 |
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IRF3, IFNG, STING1 | MAOA 3254/4885NCF1 1958/4885MAOB 3173/4885 |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | SARS1, CD14, ACE2 | MAOA 4780/4885NCF1 1854/4885MAOB 4779/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | MAOA 3504/4885NCF1 1358/4885MAOB 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.